Pitcairn Co. decreased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,818 shares of the biopharmaceutical company’s stock after selling 2,310 shares during the quarter. Pitcairn Co.’s holdings in Gilead Sciences were worth $2,740,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently modified their holdings of the company. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Gilead Sciences in the second quarter worth about $147,000. Hanson & Doremus Investment Management grew its position in shares of Gilead Sciences by 806.5% during the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 1,613 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its position in shares of Gilead Sciences by 29.3% during the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 480 shares in the last quarter. Rowland & Co. Investment Counsel ADV purchased a new stake in shares of Gilead Sciences during the second quarter worth about $153,000. Finally, Capstone Investment Advisors Netherlands B.V. purchased a new stake in shares of Gilead Sciences during the second quarter worth about $172,000. Institutional investors and hedge funds own 75.94% of the company’s stock.
GILD has been the subject of several research analyst reports. Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 target price for the company in a research report on Friday, October 13th. Berenberg Bank set a $96.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research report on Thursday, October 19th. BMO Capital Markets cut their target price on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a research report on Friday, October 27th. Credit Suisse Group reiterated a “buy” rating and set a $82.00 target price on shares of Gilead Sciences in a research report on Thursday, December 7th. Finally, Mizuho increased their target price on Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, November 8th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $85.03.
In other news, insider John F. Milligan sold 220,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $73.87, for a total value of $1,108,050.00. Following the completion of the sale, the executive vice president now directly owns 64,613 shares of the company’s stock, valued at $4,772,962.31. The disclosure for this sale can be found here. Insiders have sold a total of 461,666 shares of company stock valued at $34,072,567 in the last 90 days. 1.30% of the stock is currently owned by company insiders.
Gilead Sciences, Inc. (NASDAQ GILD) opened at $78.10 on Wednesday. The firm has a market capitalization of $101,990.00, a P/E ratio of 8.89, a price-to-earnings-growth ratio of -1.58 and a beta of 1.13. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $86.27.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating the consensus estimate of $2.13 by $0.14. The business had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm’s revenue for the quarter was down 13.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.75 EPS. equities research analysts expect that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Thursday, December 28th. Shareholders of record on Friday, December 15th were issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.66%. The ex-dividend date of this dividend was Thursday, December 14th. Gilead Sciences’s dividend payout ratio is presently 23.66%.
COPYRIGHT VIOLATION NOTICE: “Pitcairn Co. Has $2.74 Million Holdings in Gilead Sciences, Inc. (GILD)” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/01/10/pitcairn-co-has-2-74-million-holdings-in-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.